文献速递临床试验与 GCP

口服降糖药与胰岛素治疗妊娠期糖尿病的随机临床试验

Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项在荷兰25个中心开展的随机开放标签非劣效性试验纳入820例妊娠期糖尿病单胎孕妇,比较口服降糖药(二甲双胍,必要时加用格列本脲)与胰岛素对大于胎龄儿的影响。口服降糖药组大于胎龄儿发生率为23.9%,胰岛素组为19.9%,绝对风险差4.0%(95%CI -1.7%至9.8%),置信区间超过8%的非劣效界值,未达到非劣效标准。

要点

  • 口服降糖药组79%(320例)无需胰岛素即可维持血糖控制。
  • 大于胎龄儿发生率口服降糖药组23.9% vs 胰岛素组19.9%,未达非劣效。
  • 母体低血糖发生率口服降糖药组20.9% vs 胰岛素组10.9%。

核心结论

  • 对妊娠期糖尿病使用二甲双胍并在需要时加用格列本脲治疗,与胰岛素相比,在大于胎龄儿比例方面未达到非劣效性标准。

研究设计与样本

  • 随机、开放标签非劣效性试验,2016年6月至2022年11月在25个荷兰中心开展,随访于2023年5月完成。
  • 纳入820例妊娠16至34周、饮食调整2周后血糖控制不充分的妊娠期糖尿病单胎孕妇。
  • 参与者随机接受二甲双胍(起始500 mg每日一次,每3天递增至1000 mg每日两次或最高耐受剂量;n=409)或胰岛素(按当地实践处方;n=411)。
  • 若需要达到血糖目标,在二甲双胍基础上加用格列本脲,之后以胰岛素替代格列本脲。

主要发现

  • 口服降糖药组79%(n=320)维持血糖控制而无需胰岛素。
  • 大于胎龄儿(出生体重>90百分位,基于胎龄和性别)发生率:口服降糖药组23.9%(n=97) vs 胰岛素组19.9%(n=79),绝对风险差4.0%(95%CI -1.7%至9.8%),非劣效性P=.09,风险差置信区间超过8%的绝对非劣效界值。
  • 母体低血糖报告率:口服降糖药组20.9% vs 胰岛素组10.9%,绝对风险差10.0%(95%CI 3.7%-21.2%)。
  • 所有其他次要结局两组间无差异。

关键数值与推荐

  • 血糖控制不充分定义:空腹血糖>95 mg/dL(>5.3 mmol/L)、餐后1小时血糖>140 mg/dL(>7.8 mmol/L)或餐后2小时血糖>120 mg/dL(>6.7 mmol/L),经毛细血管血糖自我检测。
  • 非劣效界值为绝对风险差8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. Whether a sequential strategy of these oral agents results in noninferior perinatal outcomes compared with insulin alone is unknown. OBJECTIVE: To test whether a treatment strategy of oral glucose-lowering agents is noninferior to insulin for prevention of large-for-gestational-age infants. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label noninferiority trial conducted at 25 Dutch centers from June 2016 to November 2022 with follow-up completed in May 2023. The study enrolled 820 individuals with gestational diabetes and singleton pregnancies between 16 and 34 weeks of gestation who had insufficient glycemic control after 2 weeks of dietary changes (defined as fasting glucose >95 mg/dL [>5.3 mmol/L], 1-hour postprandial glucose >140 mg/dL [>7.8 mmol/L], or 2-hour postprandial glucose >120 mg/dL [>6.7 mmol/L], measured by capillary glucose self-testing). INTERVENTIONS: Participants were randomly assigned to receive metformin (initiated at a dose of 500 mg once daily and increased every 3 days to 1000 mg twice daily or highest level tolerated; n = 409) or insulin (prescribed according to local practice; n = 411). Glyburide was added to metformin, and then insulin substituted for glyburide, if needed, to achieve glucose targets. MAIN OUTCOMES AND MEASURES: The primary outcome was the between-group difference in the percentage of infants born large for gestational age (birth weight >90th percentile based on gestational age and sex). Secondary outcomes included maternal hypoglycemia, cesarean delivery, pregnancy-induced hypertension, preeclampsia, maternal weight gain, preterm delivery, birth injury, neonatal hypoglycemia, neonatal hyperbilirubinemia, and neonatal intensive care unit admission. RESULTS: Among 820 participants, the mean age was 33.2 (SD, 4.7) years). In participants randomized to oral agents, 79% (n = 320) maintained glycemic control without insulin. With oral agents, 23.9% of infants (n = 97) were large for gestational age vs 19.9% (n = 79) with insulin (absolute risk difference, 4.0%; 95% CI, -1.7% to 9.8%; P = .09 for noninferiority), with the confidence interval of the risk difference exceeding the absolute noninferiority margin of 8%. Maternal hypoglycemia was reported in 20.9% with oral glucose-lowering agents and 10.9% with insulin (absolute risk difference, 10.0%; 95% CI, 3.7%-21.2%). All other secondary outcomes did not differ between groups. CONCLUSIONS AND RELEVANCE: Treatment of gestational diabetes with metformin and additional glyburide, if needed, did not meet criteria for noninferiority compared with insulin with respect to the proportion of infants born large for gestational age. TRIAL REGISTRATION: Netherlands Trial Registry Identifier: NTR6134.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rademaker D, de Wit L, Duijnhoven RG, et al. Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial. JAMA. 2025. PMID: 39761054. doi:10.1001/jama.2024.23410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。